[Pharm-policy] A few USG HIV and malaria exclusive patent license notices

[James Love]

http://frwebgate1.access.gpo.gov/cgi-bin/waisgate.cgi?WAISdocID=8646818817+38+0+0&WAISaction=retrieve
Federal Register: April 3, 2001 (Volume 66, Number 64)]
[Notices] [Page 17724]
>From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr03ap01-71]                         
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: The ex vivo use of 
cyanovirin-N To Remove or Inactivate HIV in Fluid Samples

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
a exclusive license worldwide to practice the invention embodied in the 
patents and patent applications referenced below to OmniViral 
Therapeutics LLC, of Gaithersburg, MD. The patent rights in these 
inventions have been assigned to the United States of America.

   [snip]


http://frwebgate1.access.gpo.gov/cgi-bin/waisgate.cgi?WAISdocID=8646818817+39+0+0&WAISaction=retrieve
Federal Register: April 3, 2001 (Volume 66, Number 64)]
[Notices] [Page 17722]
>From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr03ap01-68]                         
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: The use of cyanovirin-N 
in a Topical Microbicide To Prevent the Transmission of HIV and Other 
Sexually Transmitted Diseases

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
a exclusive license worldwide to practice the invention embodied in the 
patents and patent applications referenced below to Biosyn, Inc., of 
Philadelphia, PA. 

   [snip]


http://frwebgate1.access.gpo.gov/cgi-bin/waisgate.cgi?WAISdocID=8646818817+40+0+0&WAISaction=retrieve
Federal Register: April 3, 2001 (Volume 66, Number 64)]
[Notices] [Page 17723-17724]
>From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr03ap01-70]                         
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: The Systemic in vivo use 
of cyanovirin-N as a Prophylactic or Therapeutic Against HIV and 
Enveloped Viruses that Cause Hemorrhagic Fever

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
a exclusive license worldwide to practice the invention embodied in the 
patents and patent applications referenced below to OmniViral 
Therapeutics LLC, of Gaithersburg, MD. 

  [snip]

http://frwebgate2.access.gpo.gov/cgi-bin/waisgate.cgi?WAISdocID=86463963+0+0+0&WAISaction=retrieve
[Federal Register: February 13, 2001 (Volume 66, Number 30)]
[Notices]  [Page 10026-10028]
>From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr13fe01-59]                         

   [snip] 

Novel Antimalarial Compounds, Methods of Synthesis Thereof, 
Pharmaceutical Compositions Comprising Same, and Methods of Using 
Same for Treatment and Prevention of Malaria

Michael R. Boyd (NCI), Gerhard Bringmann (EM), Sven Harmsen (EM) Roland 
Gotz (EM), T. Ross Kelly (EM), Matthias Wenzel (EM), Guido Francois 
(EM), J. D. Phillipson (EM), Laurent A. Assi (EM), Christopher 
Schneider (EM) Serial No. 08/195,547, filed 02/14/1994, now U.S. Patent 
5,639,761; Serial No. 08/843,582, filed 04/16/1997; Serial No. 08/
279,261, filed 07/22/1994, now U.S. Patent 5,552,550; Serial No. 08/
674,362, filed 07/01/1996, now U.S. Patent 5,763,613; Serial No. 09/
001,801, filed 12/31/1997, now U.S. Patent 6,140,339; Serial No. 09/
527,002, filed 03/16/2000; Serial No. 08/279,339, filed 07/22/1994, now 
U.S. Patent 5,571,919; Serial No. 08/363,684, filed 12/23/1994, now 
U.S. Patent 5,578,729; Serial No. 08/674,359, filed 07/01/1996, now 
U.S. Patent 5,789,594; Serial No. 08/721,084, filed 09/24/1996, now 
U.S. Patent 5,786,482

    Licensing Contact: Peter Soukas; 301/496-7056 ext. 268; e-mail: 
soukasp@od.nih.gov.
    According to data recently reported by the World Health 
Organization (WHO), the death rate from malaria exceeds one million 
individuals per year. The Public Health Service seeks exclusive or non-
exclusive licensee(s) to develop and commercialize the technology 
claimed within the portfolio of U.S. patents issued and pending, and 
corresponding international patents issued and pending. These patents 
and pending applications claim an exceptionally broad universe of novel 
naphthylisoquinoline alkaloid compounds, and methods of total synthesis 
thereof. Representative examples of these compounds have been shown to 
have potent in vitro activity against malaria parasites, including 
parasites that are highly resistant to available antimalarial drugs. 
Representative examples have also been shown to have potent in vivo 
activity against malaria parasites in animal models. Pharmaceutical 
compositions comprising these compounds, as well as methods of using 
the compounds to treat or prevent a malarial infection of a host, are 
claimed. The relative structural simplicity of this class of compounds, 
and the ready synthetic access thereto, provide unprecedented 
opportunities for structure-activity relationship (SAR), lead-
optimization and antimalarial drug development. The technology is 
further described in the following publications: J. Nat Prod. 1997 
Jul.;60(7):677-83 and Bioorg. Med. Chem. Lett. 1998 Jul.;8(13): 1729-
34.

    Dated: February 2, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 01-3605 Filed 2-12-01; 8:45 am]
BILLING CODE 4140-01-P